Work

A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.3_suppl.tps258

Authors: Zev A. Wainberg, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel H. Ahn, Joleen M. Hubbard, Jason S. Starr, Christine Burnett, Joshua Pelham, Thomas Strack, Andres Machado, Brian A. Van Tine

Institutions: University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Cedars-Sinai Medical Center, Mary Crowley Cancer Research Center, Tennessee Oncology, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, University of Miami, Mayo Clinic Hospital, Mayo Clinic, Mayo Clinic in Florida, Molecular Templates (United States), Translational Research in Oncology, Washington University in St. Louis

Language: English

Topic: Toxin Mechanisms and Immunotoxins

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3005409107

Cites:

Cited by: 1

Related to: 10